- $36.62m
- $24.64m
- 15
- 17
- 35
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.24 | ||
| Price to Tang. Book | 2.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -143.41% | ||
| Return on Equity | -180.94% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
Directors
- Alan Roemer CHM (42)
- William Ho PRE (45)
- Lawrence Lamb CFD (67)
- Patrick Mccall CFO (38)
- Kate Rochlin COO (40)
- Melissa Beelen VOP (54)
- Trishna Goswami OTH
- Peter Brandt DRC (64)
- Thomas Cirrito DRC (48)
- Travis Whitfill DRC (31)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 7th, 2018
- Public Since
- November 12th, 2020
- No. of Shareholders
- 37
- No. of Employees
- 31
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 44,123,949
- Address
- Empire State Building, NEW YORK, 10118
- Web
- https://www.in8bio.com
- Phone
- +1 6466006438
- Auditors
- CohnReznick LLP
Upcoming Events for INAB
Similar to INAB
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 21:17 UTC, shares in IN8BIO,. are trading at $0.89. This share price information is delayed by 15 minutes.
Shares in IN8BIO,. last closed at $0.89 and the price had moved by -53.7% over the past 365 days. In terms of relative price strength the IN8BIO,. share price has underperformed the S&P500 Index by -63.16% over the past year.
The overall consensus recommendation for IN8BIO,. is Buy. You can view the full broker recommendation list by unlocking its StockReport.
IN8BIO,. does not currently pay a dividend.
IN8BIO,. does not currently pay a dividend.
IN8BIO,. does not currently pay a dividend.
To buy shares in IN8BIO,. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.89, shares in IN8BIO,. had a market capitalisation of $39.22m.
Here are the trading details for IN8BIO,.:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: INAB
Based on an overall assessment of its quality, value and momentum IN8BIO,. is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in IN8BIO,. is $7.96. That is 795.49% above the last closing price of $0.89.
Analysts covering IN8BIO,. currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IN8BIO,.. Over the past six months, its share price has underperformed the S&P500 Index by -37.36%.
As of the last closing price of $0.89, shares in IN8BIO,. were trading -21.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IN8BIO,. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IN8BIO,.'s management team is headed by:
- Alan Roemer - CHM
- William Ho - PRE
- Lawrence Lamb - CFD
- Patrick Mccall - CFO
- Kate Rochlin - COO
- Melissa Beelen - VOP
- Trishna Goswami - OTH
- Peter Brandt - DRC
- Thomas Cirrito - DRC
- Travis Whitfill - DRC